Press Release: Addex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board

Geneva, Switzerland, March 3, 2020 - Addex Therapeutics Ltd (Nasdaq &

SIX: ADXN), a clinical-stage pharmaceutical company pioneering

allosteric modulation-based drug discovery and development, announced

today the appointment of one of the world's leading and most successful

neuroscience drug research and developers, Darryle D. Schoepp PhD, as

Chairman of its newly formed scientific advisory board (SAB). Dr.

Schoepp has over thirty years experience in the field, including 20

years at Eli Lilly as a scientist and leader of the neuroscience

research department, and 11 years at Merck as the neuroscience research

therapeutic area leader. During his career, Dr. Schoepp has been

involved in the discovery of over 20 novel first in class agents for

psychiatric and neurological diseases.

"Darryle has been pioneering novel approaches in neuroscience drug

discovery and development for over three decades. His contribution to

the neurology field is second to none and we are honored to have him

join our team to help steer Addex's scientific strategy," said Tim Dyer,

CEO of Addex. "Building an SAB is a key next step for Addex as we

advance our in-house discovery preclinical portfolio of drug candidates

and maintain our leadership position in allosteric modulator drug

discovery."

"I have followed the progress Addex has made in the field of allosteric

modulation since inception and have been impressed by the discoveries

they have made", said Dr. Schoepp. "I am delighted to join the team and

very much look forward to bring my experience to help Addex advance its

exciting portfolio and discovery platform."

Dr. Schoepp has published over 200 peer reviewed papers and is an

inventor of 15 U.S. patents. His research has resulted in major

contributions to the role of excitatory amino acid neurotransmitter

glutamate in disease pathophysiology, pharmacology and therapeutics. Dr.

Schoepp has been involved in the discovery of the first AMPA/kainate and

metabotropic receptor negative and positive modulators for migraine,

pain, cognition, anxiety disorders and schizophrenia. While at Lilly, he

was a co-discoverer of the compound alivimopan (Entereg), a first in

class peripherally restricted opioid antagonist for post-operative

ileus.

At Merck, Dr. Schoepp and his team built a pipeline of innovative first

in class agents for Alzheimer's disease, Parkinson's disease,

pain/migraine, and schizophrenia, including the first in class orexin

receptor antagonist Suvorexant (Belsomra) for insomnia and the first in

class oral CGRP antagonist ubrogepant (Ubrelvy) for migraine treatment.

Dr. Schoepp earned his PhD in toxicology and pharmacology from the

University of West Virginia.

About Addex Therapeutics

https://www.globenewswire.com/Tracker?data=BZn8WA5Ryp27YPs_7wVJipKOXbi9lxPbY2SWflUUVcgqX7bck8Bnfe1A-bqNOQv0h3D7E8fyvdnbM4j7KXWY9W84hGPNWSfYRIaytMEgxOQ=

Addex Therapeutics is a clinical-stage pharmaceutical company focused on

the development and commercialization of an emerging class of novel,

orally available, small molecule drugs known as allosteric modulators

for neurological disorders. Allosteric modulators offer several

potential advantages over conventional non-allosteric molecules and may

offer an improved therapeutic approach to conventional "orthosteric"

small molecule or biological drugs. Addex's allosteric modulator drug

discovery platform targets receptors and other proteins that are

recognized as essential for therapeutic intervention. Addex's lead drug

candidate, dipraglurant (an mGlu5 negative allosteric modulator or NAM),

is scheduled to enter a pivotal registration clinical trial for

Parkinson's disease levodopa induced dyskinesia (PD-LID) in Q1 20. In

parallel, dipraglurant's therapeutic use in dystonia is being

investigated in preclinical models. Addex's second clinical program,

ADX71149 (an mGlu2 positive allosteric modulator or PAM), is being

developed in collaboration with Janssen Pharmaceuticals, Inc for the

treatment of epilepsy. In addition, Addex's GABA(B) PAM program has

been licensed to Indivior PLC for the treatment of addiction.

Preclinical programs include GABA(B) PAM for CMT1A, mGlu7 NAM for PTSD,

mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's

disease and mGlu3 PAM for neurodegenerative disorders.

Press Contacts:

Tim Dyer Mike Sinclair

Chief Executive Officer Partner, Halsin Partners

Telephone: +41 22 884 15 55 +44 (0)20 7318 2955

Email: mailto:PR@addextherapeutics.com PR@addextherapeutics.com mailto:msinclair@halsin.com msinclair@halsin.com

---------------------------------------------------------------- -------------------------------------------------

Forward Looking Statements

Certain statements made in this announcement are forward-looking

statements including with respect to the creation of a trading market

for ADSs representing the Company's shares in the United States. These

forward-looking statements are not historical facts but rather are based

on the Company's current expectations, estimates, and projections about

its industry; its beliefs; and assumptions. Words such as 'anticipates,'

'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and

similar expressions are intended to identify forward-looking statements.

These statements are not guarantees of future performance and are

subject to known and unknown risks, uncertainties, and other factors,

some of which are beyond the Company's control, are difficult to predict,

and could cause actual results to differ materially from those expressed

or forecasted in the forward-looking statements. The Company cautions

securityholders and prospective securityholders not to place undue

reliance on these forward-looking statements, which reflect the view of

the Company only as of the date of this announcement. The

forward-looking statements made in this announcement relate only to

events as of the date on which the statements are made. The Company will

not undertake any obligation to release publicly any revisions or

updates to these forward-looking statements to reflect events,

circumstances, or unanticipated events occurring after the date of this

announcement except as required by law or by any appropriate regulatory

authority.

(END) Dow Jones Newswires

March 03, 2020 01:00 ET (06:00 GMT)